ELVN
Q4 2026 EPS Estimate
$-0.43
Nov 11, 2026

Analyst Sentiment

Wall St. Consensus
Buy
9 analysts·Limited coverage
75
Score
9 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
9100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$62.00
+4.1%
Consensus
$78.00
+31.0%
Bull
$82.00
+37.7%
12-Month Target Range9 analysts
$62.00$78.00$82.00
Current $59.56Consensus
Current Price
$59.56
Upside to Consensus
$18.44

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev-37.50%
EPS
FY2028
Rev+100.00%
EPS
FY2029
Rev+564669.34%
EPS
Raw consensus estimates (low / average / high) from covering analysts.
Annual
MetricFY2026EFY2027EFY2028EFY2029EFY2030E
Revenue Avg$10,000$6,250$12,500$71M$287M
Low$10,000$6,250$12,500$71M$287M
High$10,000$6,250$12,500$71M$287M
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-111M$-126M$-145M$-156M$-64M
Low$-113M$-140M$-192M$-156M$-64M
High$-88M$-112M$-98M$-156M$-64M
EPS Avg$-1.77$-2.22$-2.73$-2.76$-1.13
Low$-1.99$-2.47$-3.38$-2.76$-1.13
High$-1.55$-1.98$-1.73$-2.76$-1.13
Analysts (Rev / EPS)4 / 46 / 47 / 73 / 25 / 4
Quarterly
MetricQ3 2026Q4 2026Q1 2027Q2 2027Q3 2027Q4 2027
Revenue Avg
Low
High
EBITDA Avg
Low
High
EBIT Avg
Low
High
Net Income Avg$-28M$-34M$-32M$-36M$-38M$-40M
Low$-28M$-39M$-32M$-36M$-38M$-40M
High$-28M$-28M$-32M$-36M$-38M$-40M
EPS Avg$-0.43$-0.51$-0.49$-0.54$-0.57$-0.61
Low$-0.43$-0.59$-0.49$-0.54$-0.57$-0.61
High$-0.42$-0.43$-0.49$-0.54$-0.57$-0.61
Analysts (Rev / EPS) / 1 / 1 / 1 / 1 / 1 / 1

Earnings Surprises

Recent Analyst Actions

Aug 6, 2026Stifel Nicolaus
Enliven price target raised to $82 from $80 at Stifel
Target:$82.00
+35.1%from $60.67
Aug 6, 2026Guggenheim
Enliven Therapeutics (ELVN) PT Lowered to $78 at Guggenheim
Target:$78.00
+30.7%from $59.70
Aug 6, 2026Goldman Sachs
Enliven price target raised to $80 from $67 at Goldman Sachs
Target:$80.00
+34.0%from $59.70
Jul 21, 2026Goldman Sachs
Enliven price target raised to $67 from $59 at Goldman Sachs
Target:$67.00
+29.7%from $51.67
Jul 9, 2026H.C. Wainwright
Enliven price target raised to $65 from $56 at H.C. Wainwright
Target:$65.00
+28.0%from $50.80
Jul 1, 2026Stifel Nicolaus
Enliven price target raised to $80 from $60 at Stifel
Target:$80.00
+57.9%from $50.68
Jun 8, 2026Stifel Nicolaus
Enliven initiated with a Buy at Stifel
Target:$60.00
+78.4%from $33.63
Jun 2, 2026Mizuho Securities
Enliven Therapeutics (ELVN) PT Raised to $62 at Mizuho
Target:$62.00
+65.3%from $37.51
May 12, 2026Guggenheim
Enliven initiated with a Buy at Guggenheim
Target:$80.00
+102.1%from $39.59
May 8, 2026Goldman Sachs
Enliven price target raised to $59 from $41 at Goldman Sachs
Target:$59.00
+39.0%from $42.45
Jun 16, 2025Robert W. Baird
Enliven price target raised to $52 from $40 at Baird
Target:$52.00
+125.2%from $23.09
Mar 21, 2025H.C. Wainwright
Enliven price target raised to $39 from $37 at H.C. Wainwright
Target:$39.00
+85.0%from $21.08
Nov 15, 2024Robert W. Baird
Enliven Therapeutics (ELVN) PT Raised to $40 at Baird
Target:$40.00
+66.3%from $24.05
Sep 23, 2024Mizuho Securities
Mizuho Reiterates Outperform Rating on Enliven Therapeutics (ELVN)
Target:$39.00
+63.9%from $23.80
Jun 10, 2024Robert W. Baird
Baird Starts Enliven Therapeutics (ELVN) at Outperform
Target:$32.00
+41.7%from $22.58
Apr 9, 2024Mizuho Securities
Mizuho Starts Enliven Therapeutics (ELVN) at Buy
Target:$34.00
+85.8%from $18.30
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.